Pacific Edge
Healthcare Services · New Zealand · 51-200 Employees
View Company Info for Free
Overview
Headquarters
87 St David St, Dunedin, Otago, 9016, Ne...Phone Number
+64 800555563Website
www.pacificedgedx.comRevenue
$15.8 MillionStock Symbol
PEBIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
3
2
3
3
About Pacific Edge
Pacific Edge is the only company in the world which has a suite of molecular diagnostic tests in bladder cancer that addresses different needs throughout the diagnostic and treatment pathway - from investigation of haematuria (blood in the urine) through to the management of patients who have the disease and who are coming back to the clinic for evaluation of the recurrence of the disease. Pacific Edge is focused on positioning its highly accurate, non-invasive and cost effective Cxbladder technology as the preferred diagnostic tool for clinicians and urologists, and is seeing increasing demand and uptake from both private and public healthcare providers.Explore more
Pacific Edge Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pacific Edge your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pacific Edge, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pacific Edge has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Pacific Edge recently announced quarterly report
Click to see if Pacific Edge had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Pacific Edge
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Pacific Edge is spiking on competitors!
Funding: Get notified immidiatlly once Pacific Edge has new funding data
Product Launch: Get notified when Pacific Edge launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Pacific Edge is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Pacific Edge is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Pacific Edge.
Pacific Edge financials insights
Gather financial insights about Pacific Edge, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$16M
Other Financing Round
$20.7M
Pacific Edge Tech Stack
A closer look at the technologies used by Pacific Edge
Most Recent Scoops
Earnings
Pacific Edge has reported reductions across all major operating expense categories for FY2026, including lower lab operation costs consistent with reduced US volumes, an 8.2% decline in research expenses, a 20% reduction in sales and marketing costs in H2 versus H1 and a 13.2% year-on-year decline, and lower general and administrative costs, all reflecting the company's ongoing cash preservation efforts.
Spending/Investment, Research & Development, Sales, Laboratory Operations
Project
Pacific Edge has reported that operating expenses declined 9.5% compared to FY2025, with H2 2026 expenses down a further 11.9% relative to H1 of the same year, and net cash outflows from operating activities decreasing 32.1% in H2 compared to H1, reflecting the company's focus on cash preservation.
Spending/Investment, Finance, Financial Operations
Earnings
Pacific Edge has reported that operating revenue fell 47.4% compared to FY2025, predominantly due to the loss of Medicare coverage, which reduced both test volumes and revenue per test, with the company also reverting to cash accounting for Medicare revenue during the current financial year.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Pacific Edge has reported that its Asia Pacific commercial and clinical operations, excluding R&D costs, recorded an FY2026 cash burn of NZD 0.6 million on a direct cost basis, trending toward profitability, supported by repricing efforts and the anticipated wider adoption of Cxbladder Triage+ over legacy products.
Clinical Operations, Pricing
Earnings
Medical Research, Clinical Operations
Pacific Edge News & Media
Expert Panel Expresses Clear Support for Urine-Based Biomarkers in Hematuria Evaluation
Global cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today summarizes the opinions expressed by the panel of experts during the Contractor Advisory Committee (CAC) meeting organized by Novitas on Thurs 19 Feb regarding the use of urine-based biomarker tests in the evaluation of...Kaiser Study Backs Cxbladder Triage Ahead of Medicare Panel
Global cancer diagnostics company Pacific Edge (NZX, ASX: PEB) welcomes the publication, in the journal 'Urology Practice', of a Kaiser Permanente study demonstrating the real-world Clinical Utility of Cxbladder Triage in the largest ever urine-based biomarker study on patients presenting...Pacific Edge Appoints Chief Commercial Officer - sharechat.co.nz
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces the appointment of James Vaughn, R.Ph. into the new role of Chief Commercial Officer (CCO) to drive the adoption of Cxbladder
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Pacific Edge
Sign Up For FreeTo access detailed company insights
Pacific Edge is the only company in the world which has a suite of molecular diagnostic tests in bladder cancer that addresses different needs throughout the diagnostic and treatment pathway - from investigation of haematuria (blood in the urine) through to the management of patients who have the disease and who are coming back to the clinic for ev... Read More
